29,860
Total Claims
$3.7M
Drug Cost
1,814
Beneficiaries
$2,053
Cost/Patient
Peer Comparison vs. 6,382 Endocrinology providers
-48%
Cost per patient vs peers
$2,053 vs $3,933 avg
-31%
Brand preference vs peers
35.5% vs 51.2% avg
Brand vs Generic
65% generic
Brand: 10,358 claims · $3.4M
Generic: 18,817 claims · $283K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phos/Metformin Hcl | 699 | $483K |
| Levothyroxine Sodium | 4,783 | $295K |
| Empagliflozin/Metformin Hcl | 399 | $251K |
| Insulin Glargine,hum.Rec.Anlog | 410 | $240K |
| Insulin Lispro | 269 | $187K |
| Empagliflozin | 165 | $129K |
| Sitagliptin Phosphate | 194 | $126K |
| Dapagliflozin Propanediol | 174 | $120K |
| Linagliptin | 168 | $106K |
| Insulin Lispro Protamin/Lispro | 114 | $101K |
| Linagliptin/Metformin Hcl | 144 | $91K |
| Insulin Nph Hum/Reg Insulin Hm | 213 | $85K |
| Sitagliptin Phos/Metformin Hcl | 136 | $78K |
| Insulin Lispro | 135 | $76K |
| Insulin Glargine,hum.Rec.Anlog | 156 | $71K |
Prescribing Profile
Patient Profile
73
Avg Age
72%
Female
1.90
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About